Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy

التفاصيل البيبلوغرافية
العنوان: Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy
المؤلفون: Emily R Finch, Jun J. Yang, John C. Panetta, Deqing Pei, Colton Smith, Jeffrey E. Rubnitz, Cheng Cheng, Raul C. Ribeiro, Monika L. Metzger, Mary V. Relling, Seth E. Karol, Nancy Kornegay, William E. Evans, Yiwei Liu, Kristine R. Crews, Sima Jeha, Wenjian Yang, Ching-Hon Pui, Hiroto Inaba, Tanja A. Gruber
المصدر: Haematologica. 107:371-380
بيانات النشر: Ferrata Storti Foundation (Haematologica), 2021.
سنة النشر: 2021
مصطلحات موضوعية: Pegaspargase, medicine.medical_specialty, Chemotherapy, Asparaginase, Cyclophosphamide, Dose, Mercaptopurine, business.industry, medicine.medical_treatment, Cytarabine, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Gastroenterology, chemistry.chemical_compound, chemistry, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Escherichia coli, Humans, Medicine, Dosing, business, medicine.drug
الوصف: Chemotherapy dosages are often compromised, but most reports lack data on dosages that are actually delivered. In two consecutive acute lymphoblastic leukemia trials that differed in their asparaginase formulation, native E. coli L-asparaginase in St. Jude Total 15 (T15, n=365) and pegaspargase in Total 16 (T16, n=524), we tallied the dose intensities for all drugs on the low-risk or standard-risk arms, analyzing 504,039 dosing records. The median dose intensity for each drug ranged from 61-100%. Dose intensities for several drugs were more than 10% higher on T15 than on T16: cyclophosphamide (P
تدمد: 1592-8721
0390-6078
DOI: 10.3324/haematol.2021.278411
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42263f52a10129277be54dfd0018486a
https://doi.org/10.3324/haematol.2021.278411
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....42263f52a10129277be54dfd0018486a
قاعدة البيانات: OpenAIRE
الوصف
تدمد:15928721
03906078
DOI:10.3324/haematol.2021.278411